scholarly journals MORPHOLOGICAL FEATURES AND IMMUNOPHENOTYPIC ASPECTS OF HYBRID KIDNEY TUMOR

2020 ◽  
Vol 10 (2) ◽  
pp. 13-21
Author(s):  
E. А. Kogan ◽  
Y. I. Osmanov ◽  
V. I. Shchekin ◽  
G. А. Demyashkin ◽  
A. V. Kaem
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Immunohistochemical Analysis ◽  
Carcinoma Cells ◽  
Kidney Tumors ◽  
Caveolin 1 ◽  
Clinical Center ◽  
Oncocytic Tumor ◽  
Immunohistochemical Studies

A hybrid oncocytic/chromophobic tumor or a low malignant oncocytic tumor is not officially included in the clas- sification of 2016 WHO kidney tumors, however, in the literature, some authors consider this tumor as an independent nosological unit. A number of authors describe a hybrid oncocytic / chromophobic tumor consisting exclusively of relatively small oxyphilic cells resembling both oncocytes and chromophobic renal carcinoma cells at the same time. The development of morphological and immunohistochemical criteria for a hybrid oncocytic / chromophobic tumor is an important link in the differential diagnosis of renal cell carcinomas with oncocytic morphology. The aim of the study is a comparative analysis of the morphological, histochemical, immunophenotypic parameters of oncocytoma, chromophobic renal cell carcinoma and hybrid oncocytic / chromophobic tumor. Materials and methods. The study was performed on operational material from 162 patients undergoing surgical treatment at the Urological Clinic I. M. Sechenov and the Urology Center of the Scientific Clinical Center (NCC) of Russian Railways for kidney oncocytoma and chromophobic renal cell carcinoma from 2011 to 2017. Immunohistochemical studies were performed on paraffin sections according to the standard protocol. Antibodies used: EABA, Caveolin-1, MOC31, CyclinD1, CD10, CD117, EpCAM, CK7, DOG1, CAM5.2, CK19, E-Cadherin, Parvalbumin, KSC, PAX2, PAX8, S100A1 and MUC-1. Results. Based on the performed morphological and immunohistochemical analysis of 162 tumors in 61 (38%) cases revealed oncocytoma, in 35 (22%) showed cases classical chromophobic renal cell carcinoma, in 59 (36%) samples eosinophilic chromophobic renal cell carcinoma and 7 (4%) cases had a hybrid oncocytic/ chromophobic tumor. Conclusion. In some cases, a hybrid oncocytic / chromophobic tumor can be represented exclusively from “hybrid” cells with borderline signs of oncocytoma and eosinophilic chromophobic renal cell carcinoma.

scholarly journals Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors

2020 ◽  
pp. 145-145
Author(s):  
Snezana Mugosa ◽  
Zoran Dzamic ◽  
Majda Sahman-Zaimovic ◽  
Nevenka Lukovac-Janjic
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adverse Drug Reactions ◽  
Renal Cell ◽  
Subcutaneous Tissue ◽  
Significant Risk ◽  
Drug Reactions ◽  
Kidney Tumors ◽  
Clinical Center

Background/Aim: Kidney tumors account for 2-3% of all tumors. Renal cell carcinoma is the tenth most common malignancy. Sunitinib ise used as the first treatment line in patients with a good and intermediate prognosis. The main goal of this study is to analyze the risk factors, frequency and adverse drug reactions (ADRs) of sunitinib in patients with metastatic renal cell carcinoma. Methods: The retropective study included 170 patients treated in Clinic for Oncology of the Clinical Center of Montenegro, Urology Clinic of the Clinical Center of Serbia and Clinic for Oncology of the Clinical Center Nis. As a data source, we used patient medical histories and/or electronic patient records. ADRs were characterized by using Rawlins and Thompson classification. Each ADRs severity was assessed in accordance with the WHO criteria. Causality was assessed using the Naranjo probability scale. Results: Adverse drug reactions of sunitinib occurred in 152 patients (89,4%). ADRs were 89% type A and 11% type C. Disorders of the blood and lymphatic system, gastrointestinal disorders and disorders of the skin and subcutaneous tissue were the most common manifestations of ADRs of sunitinib. Causality assesment was most commonly classified as certain (60%). Serious ADRs occurred in 4.5% of patients. Most patients recovered without consequences. The most common manifestations of ADRs were: leukopenia, hypothyroidism, thrombocytopenia, diarrhea, stomatitis, asthenia and hypertension. All ADRs were expected. The number of concomitant medications and the duration of therapy were shown to be the most significant risk factors for adverse reactions to sunitinib. Conclusion: Our study shows that the incidence of ADRs of sunitinib in patients with kidney cancer is high. The ADRs were mostly moderate and mild in intensity and occurred as a consequence of the pharmacological action of the drug. It is necessary to conduct continuous education of medical oncologists in the field of the safe use of drugs monitoring, as well as patients on sunitinib therapy, in order to improve their awareness of the ADRs of sunitinib and the risk factors that lead to them, with the aim of reducing their frequency.

995: Immunohistochemical Analysis of Tumor Polyamines Discriminates High Risk Patients Undergoing Nephrectomy for Renal Cell Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 263-263
Author(s):  
Nathalie Rioux-Leclercq ◽  
Florence Jouan ◽  
Pascale Bellaud ◽  
Jacques-Philippe Moulinoux ◽  
Karim Bensalah ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Immunohistochemical Analysis ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals TNF-α Induces Epithelial–Mesenchymal Transition of Renal Cell Carcinoma Cells via a GSK3β-Dependent Mechanism

2012 ◽  
Vol 10 (8) ◽  
pp. 1109-1119 ◽  
Author(s):  
Ming-Yi Ho ◽  
Shye-Jye Tang ◽  
Mei-Jen Chuang ◽  
Tai-Lung Cha ◽  
Jing-Yao Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Epithelial Mesenchymal Transition ◽  
Carcinoma Cells ◽  
Mesenchymal Transition ◽  
Tnf Α ◽  
Dependent Mechanism

scholarly journals Clinicopathologic features of TDO2 overexpression in renal cell carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Quoc Thang Pham ◽  
Daiki Taniyama ◽  
Yohei Sekino ◽  
Shintaro Akabane ◽  
Takashi Babasaki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
In Silico Analysis ◽  
Immunohistochemical Analysis ◽  
Rna Seq ◽  
Anoikis Resistance ◽  
Silico Analysis ◽  
Proliferation And Invasion

Abstract Background Tryptophan 2,3-dioxygenase (TDO2) is the primary enzyme catabolizing tryptophan. Several lines of evidence revealed that overexpression of TDO2 is involved in anoikis resistance, spheroid formation, proliferation, and invasion and correlates with poor prognosis in some cancers. The aim of this research was to uncover the expression and biofunction of TDO2 in renal cell carcinoma (RCC). Methods To show the expression of TDO2 in RCC, we performed qRT-PCR and immunohistochemistry in integration with TCGA data analysis. The interaction of TDO2 with PD-L1, CD44, PTEN, and TDO2 expression was evaluated. We explored proliferation, colony formation, and invasion in RCC cells line affected by knockdown of TDO2. Results RNA-Seq and immunohistochemical analysis showed that TDO2 expression was upregulated in RCC tissues and was associated with advanced disease and poor survival of RCC patients. Furthermore, TDO2 was co-expressed with PD-L1 and CD44. In silico analysis and in vitro knockout of PTEN in RCC cell lines revealed the ability of PTEN to regulate the expression of TDO2. Knockdown of TDO2 suppressed the proliferation and invasion of RCC cells. Conclusion Our results suggest that TDO2 might have an important role in disease progression and could be a promising marker for targeted therapy in RCC. (199 words)

Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro

2011 ◽  
Vol 22 (8) ◽  
pp. 749-762 ◽  
Author(s):  
Nicoletta Gagliano ◽  
Letizia Pettinari ◽  
Massimo Aureli ◽  
Carla Martinelli ◽  
Elena Colombo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Malignant Phenotype
Sign in / Sign up

Export Citation Format

Share Document